NDA 020309 · Hospira
Magnesium Sulfate In Plastic Container
Magnesium Sulfate · Injection
Last checked: Nov 20, 2026Latest source record: Jul 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Jun 24, 1994
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
17
13 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 24, 2026.
INDICATIONS AND USAGE Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 24, 1994 Original approval · Type 5 - New Formulation or New Manufacturer Review
5 products under this application
- MAGNESIUM SULFATE IN PLASTIC CONTAINER · MAGNESIUM SULFATE 20GM/500ML (40MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- MAGNESIUM SULFATE IN PLASTIC CONTAINER · MAGNESIUM SULFATE 4GM/50ML (80MG/ML) · INJECTABLE, INJECTION · Discontinued · TE AP
- MAGNESIUM SULFATE IN PLASTIC CONTAINER · MAGNESIUM SULFATE 40GM/1000ML (40MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- MAGNESIUM SULFATE IN PLASTIC CONTAINER · MAGNESIUM SULFATE 2GM/50ML (40MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- MAGNESIUM SULFATE IN PLASTIC CONTAINER · MAGNESIUM SULFATE 4GM/100ML (40MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Magnesium Sulfate In Plastic Container" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- burkholderia test positive8
- endotracheal intubation5
- dyspnoea4
- covid-193
- no adverse event3
- respiratory rate decreased3
- extrapyramidal disorder2
- respiratory failure2
- therapeutic product effect increased2
- tremor2
- acute kidney injury1
- acute respiratory failure1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 13 |
| 2024 | 1 |
Recalls
2 FDA enforcement reports for this application.
Jan 5, 2016 · Class I · Terminated
Labeling: Incorrect Barcode: Primary bag labeling may be mislabeled with the wrong barcode which scans in as heparin sodium.
Apr 5, 2012 · Class III · Terminated
Superpotent (Single Ingredient) Drug: Above specification assay results for percentage of magnesium sulfate.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.